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MitochondriaThe outbreak of COVID-19 was declared a Public Health Emer-
gency of International Concern in January 2020, scientists all over
the world found new ways of progressing scientific research and
maintaining or even expanding collaboration in a virtual setting.
“Aging Science Talks” were one of the most successful initiatives
that engaged scientists all over the world working in the field of
aging and highly relevant in the context of the pandemic.
Aging is the biggest risk factor for developing chronic disorders
such as heart disease, type 2 diabetes, chronic obstructive pulmo-
nary disease (COPD), stroke, neurodegenerative diseases, chronic
kidney diseases (CKDs) and cancer [1,2]. Aging is a complex process
with detrimental effects on cell and tissue homeostasis which ul-
timately effects organ function [3]. Several mechanistic pathways
have been associated with aging, such as an increase in inflam-
mation, oxidative stress, DNA mutations, mitochondrial dysfunc-
tion, accumulation of senescence cells and disrupted proteostasis
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(http://creativecommons.org/licenses/by/4.0/).accompanied by an increase in health span, which can subse-
quently result in a greater strain on healthcare systems [7]. The
susceptibility of the aged individual suffering chronic disorders has
been recently highlighted due to the Coronavirus disease (COVID-
19) caused by severe acute respiratory syndrome coronavirus-2
(SARS-CoV-2). Emerging data show that older people and those
with certain underlying medical conditions, such as obesity or
diabetes, are particularly affected by SARS-CoV-2 [8e11]. Aging and
COVID-19 are associated with changes in systemic inflammation
and dysregulation of the immune system function [8] and it has
been suggested that COVID-19 survivors, especially those requiring
mechanical assisted ventilation will suffer from frailty [12]. Early
studies have shown the existence of musculoskeletal deterioration
in patients with COVID-19, although long-term follow-up studies
are needed [13].
Frailty is largely associated with sarcopenia, aging-related loss
of muscle mass and function, characterised by a progressive and
degenerative loss of skeletal muscle mass, quality, and strength
during aging [14]. Sarcopenia affects 5e13% of 60e70 year olds and
up to 50% of people over 80 [15]. Currently, diet and exercise remain
the only effective interventions, that aim to maintain muscle mass
and force, however no therapeutic has been established to suc-
cessfully treat sarcopenia [16,17]. The molecular mechanismsAi Communication Co., Ltd. This is an open access article under the CC BY license
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transcriptome and proteome changes, as well as epigenetic changes
in skeletal muscle during aging have been identified [21] [e] [25].
The role of microRNAs (miRNAs, miRs) as epigenetic modifiers
in regulating loss of muscle mass and function has become
increasingly recognised (reviewed in Ref. [17]). miRs are short, non-
coding RNAs which regulate the expression of approximately 2/3
human genes [26]. miRs bind to their targets, usually within the
30UTR region of mRNAs, via sequence complementarity. This results
in gene expression regulation at the post-transcriptional level,
through the degradation of the target mRNA(s) and/or translational
block, ultimately resulting in decreased protein levels [26].
In skeletal muscle, miRs have been demonstrated to control
multiple biological processes, including development, regenera-
tion, and aging (reviewed in Ref. [27,28]). A number of miRs are
involved in the regulation of muscle protein synthesis, that target
regulators involved maintaining the balance between muscle at-
rophy and hypertrophy, and including regeneration of skeletal
muscle [29e32]. Early studies in humans demonstrated differential
expression of miRs in skeletal muscle during aging [24,33]. We and
others have demonstrated the role of miRs in aging-associated
processes in skeletal muscle, such as satellite cell senescence and
inflammation [30,34,35].
Bioinformatic analyses of non-coding RNAs and transcripts in
human and rodent muscle during aging have identified miR-181a
as a potentially key regulator of muscle mass and function during
aging [25,36]. The miR-181 family of miRs includes four miRs in
humans and rodents: miR-181a, b, c and d. miR-181a and b are
clustered together at two genomic loci on chromosomes 1 and 9
and miR-181c and d are clustered on chromosome 19 in humans.
Interestingly, the two miR-181 clusters producing two members of
miR-181 family each, have been shown to have divergent roles in
myocardial function [37]. The miR-181 family is predicted to
regulate over 1000 genes [38]. Unsurprisingly, the miR-181 family
has been shown to regulate multiple genes in many tissues,
including genes associated with mitochondrial dynamics
[37,39e48].
In skeletal muscle, miR-181a appears to be the predominant
miR-181 family member in skeletal muscle affected by aging and
has been suggested as biomarker of muscular health [36,46]. miR-
181 has also been demonstrated to be upregulated in muscle dur-
ing exercise and predicted to regulate transcription factors and co-
activators involved in the adaptive response of muscle to exercise
[49]. Based on computer simulation models, miR-181a was pre-
dicted to regulate muscle atrophy and hypertrophy through its
target genes: HOXA11 by inhibiting MYOD, and SIRT1, through
regulating FoxO3 signalling [50] (Fig. 1). Indeed, we and others
confirmed these as miR-181a direct targets [25,50]. More recently,
miR-181 family of miRs gained more attention due to their regu-
lation of processes associated with mitochondrial dynamics and
directly targets PARK2 and p62/SQSTM1 [44,46,51] (see Fig. 1).
Mitochondrial dysfunction is one of the hallmarks of aging [5].
During aging, skeletal muscle is characterised by a loss of mito-
chondrial content [52] and disrupted mitochondrial turnover,
particularly in sedentary individuals [46,53e56]. A number of
studies to date suggest that miR-181a may be a global regulator of
mitochondrial dynamics, redox homeostasis and potentially energy
balance of the whole organism [34,39,44,46,51].
For example, post-stroke treatment with antagomiR-181a has
been shown to reduce infarction size through regulating BCL-2
expression and NF-KB activation [57]. The regulation of Bcl-1 by
miR-181 has also been demonstrated in astrocytes [40]. In this
study, reduction of miR-181 levels and concomitant upregulation of
BCL-2 led to a controlled increase in oxidative stress and antioxi-
dant defence. Furthermore, inhibition of miR-181a was reported toprotect the brain from stroke via regulation of GRP78 and miR-
181a/b downregulation has been proposed to protect retinal neu-
rons from cell death through regulating mitochondrial homeostasis
[44,58].
The role of miR-181 in regulating the response to oxidative
stress has also been studied in the context of myocardial function
[37]. miR-181c levels were shown to negatively correlate to those of
COX1, whereas miR-181a/b were suggested to regulate the levels of
PTEN [37]. The authors proposed that decreased levels of miR-181c
resulted in COX1 upregulation and dysfunction of complex IV and
increased ROS production in vitro [59].
It therefore appears that miR-181 may play a critical role in
regulating redox homeostasis and potentially mitochondrial dy-
namics in nervous and cardiac cells, with studies suggesting that
inhibition of miR-181 may prevent cell death and improve anti-
oxidant response via targeting BCL-1, BCL-2, GRP78 and PTEN.
Interestingly, in other tissues miR-181 has been demonstrated to be
a positive regulator of metabolism, mitochondrial function and
redox homeostasis [60].
miR-181 has been proposed to function as the primary meta-
bolic rheostat in immune cells trough targeting of PTEN and PI3K
signaling [61]. Loss of miR-181a1/b1 in thymocytes was demon-
strated to result inmajor metabolic reprogramming: a dysregulated
expression of key components of the glycolytic, pentose phosphate
and nucleotide biosynthetic pathways and miR-181a1/b1-deficient
cells failed to reach the biosynthetic potential of proliferating thy-
mocytes [62]. This led to suboptimal glucose uptake, reduced
glycolytic rates, and impaired metabolic fitness in miR-181-
deficient cells [62].
Moreover, mice lacking multiple miR-181 alleles display im-
mune phenotypes in B-cell development and T-cell homeostatic
proliferation [63]. Interestingly, miR-181a1/b1; miR-181a2/b2
double knockout mice show reduced survival when compared to
littermates and a significant reduction in body size [62]. Further-
more, no data on triple knock-out mice exists, which may suggest
that complete deficiency of the miR-181 family is lethal [61].
Consistently, the role of miR-181 as a positive regulator of
metabolism though regulation of PTEN, overexpression of the miR-
181a/b1 cluster was also demonstrated to enhance osteogenesis
through protein synthesis and mitochondrial metabolism [51].
Moreover, oxygen consumption rate and ATP-linked respiration
were increased by miR-181a/b1 through its regulation of the PTEN/
PI3K signalling [51]. In the context of cancer, miR-181a has been
shown to have pro- but also anti-oncogenic role [39,41,64e66]. In
CD8þ T cells, interferon-g is regulated by miR-181a during differ-
entiation [67].
In our study, using miR gain- and loss-of-function approaches,
we have demonstrated that miR-181 regulates skeletal muscle size
and function during aging through regulating mitochondrial dy-
namics [46]. Specifically, we demonstrated that miR-181a prevents
the accumulation of Park2, DJ-1 and p62 in muscle during aging.
This accumulation could be associated with disrupted mitochon-
drial turnover observed during aging [46]. Using the mitoQC re-
porter construct for the investigation of mitophagic flux [68], we
demonstrated that miR-181a overexpression promotes mitophagy.
The increased mitophagic flux may be associated with activation of
alternative pathways than Pink/Parkin pathway, such as receptor-
mediated mitophagy via BNIP3. Mitochondrial turnover is regu-
lated by a number of different pathways and the exact regulatory
mechanisms have not yet been fully determined [69,70]. Interest-
ingly, we also observed a parallel increase in markers of mito-
chondrial biogenesis, e.g. increased PGC1a expression, following
miR-181a overexpression in skeletal muscle [46]. A coupling of
mitochondrial biogenesis and mitophagy has been previously
observed in C. elegans and proposed to be mediated via NRF2
Fig. 1. The role of miR-181a in skeletal muscle aging.
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in increased mitochondrial content and increased myofibre size
and muscle force in skeletal muscle from old mice [46]. Interest-
ingly, the positive effects of miR-181 on mitochondrial function
have been demonstrated in other tissues such as chondrocytes [72].
Whilst most data agree on the importance of miR-181 in regu-
lation of mitochondrial dynamics, redox homeostasis and energy
balance, it appears that the role of miR-181a could be context-
dependent as has been reported for other miRs [30,73]. Different
members of miR-181 family were shown to have divergent function
in myocardial function [37,38,42,43]. miR-181 family members are
ubiquitously expressed and the dose dependent reduction in or-
ganism size and viability following reduction of levels of the miR-
181 family members suggests the critical role of this miR family
in metabolic fitness and proliferation [61]. Moreover, miR-181
target genes such as Parkin or PTEN are conserved among species
and it has been suggested that this family of miRNAs has evolved to
provide anabolic robustness during development [61]. This may
also suggest the important role of miR-181 family in a multitude of
disorders associated with changes in mitochondrial dynamics and
oxidative stress, such as sarcopenia or aging.
The potential of miRs as novel therapeutics for various disorders
has been proposed due to their implication in regulating multiple
pathways and involvement in many disease states including aging
and sarcopenia [25,27,35]. Despite multiple miR-based therapies
being in clinical trials, nomiR-based drug has been yet approved for
use [74e79]. Since the recent approval of the first RNA drug for
disease (2018) with no other treatment options, an interest in RNAtherapeutics has increased. Onpattro (patisiran) infusion has been
used to treat peripheral nerve disease (polyneuropathy) caused by
hereditary transthyretin-mediated amyloidosis (hATTR) in adult
patients [80]. As miRs regulate the expression of multiple genes
simultaneously, they are attractive therapeutic targets for disorders
with a complex molecular background, such as sarcopenia. miRs
are small, charged, and water-soluble molecules and can be injec-
ted intravascularly or subcutaneously [81]. Moreover, synthetic
miRs and their inhibitors can be efficiently delivered, into muscle
without a systemic immune response [74,82]. Furthermore, various
miR-based therapies are undergoing clinical trials, miR mimics and
inhibitors (antagomiRs, antimiRs) [74]. Some of the remaining is-
sues that remain to be resolved before miRs can enter the drug
market are potential off-target effects and tissue-specific delivery.
These would be of significance when designing a miR-based ther-
apeutic for muscle disorders, as delivery would likely be via IV
injection which could result in systemic expression. Nevertheless,
miR-based approaches have shown efficacy in diseases such as
cancer, hepatitis C and heart abnormalities [75,83]. Emerging data
for miRs as therapeutic is encouraging and with emerging tech-
nologies, miR-based approaches may provide functional in-
terventions for preventing aging- and disease-related loss of
muscle mass and strength.Declaration of competing interest
The authors declare no conflict of interest.
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